Kilitch Drugs

Which are the latest news on Kilitch Drugs?

Why is Kilitch Drugs (India) Ltd falling/rising?

As of 05-Sep, Kilitch Drugs (India) Ltd's stock price is rising to Rs 180.10, up 4.98%, supported by strong buying interest and increased investor participation. The stock has outperformed its sector and shows a bullish trend, with significant delivery volume indicating positive market sentiment.

As of 05-Sep, Kilitch Drugs (India) Ltd's stock price is rising, currently at Rs 180.10, reflecting an increase of Rs 8.55 or 4.98%. This upward movement is supported by several factors. The stock has outperformed its sector by 5.43% today and has shown consecutive gains over the last two days, with a total return of 5.08% during this period. Additionally, the stock reached an intraday high of Rs 180.1, indicating strong buying interest.<BR><BR>Investor participation has also increased, as evidenced by a significant rise in delivery volume, which was up by 220.67% compared to the 5-day average. This suggests that more investors are willing to hold the stock rather than trade it, which is typically a positive sign for price stability and growth.<BR><BR>Moreover, the stock's current price is above its 5-day, 20-day, 100-day, and 200-day moving averages, indicating a bullish trend, although it remains below the 50-day moving average. Overall, these factors contribute to the stock's rising price, reflecting positive market sentiment towards Kilitch Drugs (India) Ltd.

Who are in the management team of Kilitch Drugs?

The management team of Kilitch Drugs includes Mukund P Mehta (Managing Director), Bhavin M Mehta and Mira Bhavin Mehta (Whole-time Directors), and independent directors Hemang Engineer, Murti Vasudev Krishna, and Venkita Subramanian Rajan, along with Pushpa Nyoupane as Company Secretary & Compliance Officer.

The management team of Kilitch Drugs includes the following individuals:<BR><BR>1. Mukund P Mehta - Managing Director<BR>2. Bhavin M Mehta - Whole-time Director<BR>3. Mira Bhavin Mehta - Whole-time Director<BR>4. Hemang Engineer - Independent Director<BR>5. Murti Vasudev Krishna - Independent Director<BR>6. Venkita Subramanian Rajan - Independent Director<BR>7. Pushpa Nyoupane - Company Secretary & Compliance Officer<BR><BR>If you need more details about their roles or contributions, feel free to ask!

What does Kilitch Drugs do?

Kilitch Drugs (India) Ltd is a micro-cap pharmaceutical company founded in 1992, specializing in manufacturing and marketing a wide range of pharmaceutical formulations. As of June 2026, it reported net sales of 45 Cr and a net profit of 3 Cr, with a market cap of INR 591 Cr.

Overview:<BR>Kilitch Drugs (India) Ltd is a leading and rapidly growing pharmaceutical company in the micro-cap category, specializing in the manufacturing, supplying, and marketing of a broad range of pharmaceutical formulations across various dosage forms.<BR><BR>History:<BR>Incorporated in May 1992, Kilitch Drugs has established itself as a significant player in the pharmaceutical industry. The latest quarterly results reported net sales and net profit for June 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 45 Cr (Quarterly Results - Jun 2026)<BR>- Net Profit: 3 Cr (Quarterly Results - Jun 2026)<BR>- Market-cap: INR 591 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 20.00<BR>- Industry P/E: 37<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: 0.07<BR>- Return on Equity: 10.79%<BR>- Price to Book: 2.11<BR><BR>Contact Details:<BR>Address: C-301/2 MIDC TTC Indl Area, Pawane Village Thane Maharashtra : 400705<BR>Tel: 91-022-27670322/27680913/65144185<BR>Email: info@kilitch.com<BR>Website: http://www.kilitch.in

Who are the peers of the Kilitch Drugs?

Kilitch Drugs' peers include Shree Ganesh Rem, Bafna Pharma, Amanta Healthcare, Zim Laboratories, Valiant Laboratories, Albert David, Jenburkt Pharma, Haleos Labs, and Influx Health. Kilitch Drugs has good growth and capital structure, with a 1-year return of 3.44%, lower than Bafna Pharma's 198.53% but higher than Jenburkt Pharma's -4.08%.

Peers: The peers of Kilitch Drugs are Shree Ganesh Rem, Bafna Pharma., Amanta Healthcar, Zim Laboratories, Valiant Laborato, Albert David, Jenburkt Pharma, Haleos Labs Limi, and Influx Health.<BR><BR>Quality Snapshot: Excellent management risk is observed at Albert David and Jenburkt Pharma, while Average management risk is found at Shree Ganesh Rem, Amanta Healthcar, Zim Laboratories, Kilitch Drugs, Haleos Labs Limi, and Influx Health. Below Average management risk is present at Bafna Pharma., Valiant Laborato. Growth is rated as Good for Kilitch Drugs and Influx Health, while Average growth is seen at Shree Ganesh Rem, and Below Average growth is noted for Bafna Pharma., Amanta Healthcar, Zim Laboratories, Valiant Laborato, Albert David, Jenburkt Pharma, and Haleos Labs Limi. Excellent capital structure is held by Shree Ganesh Rem, Albert David, and Influx Health, while Good capital structure is attributed to Kilitch Drugs and Valiant Laborato, and Below Average capital structure is noted for Amanta Healthcar and Haleos Labs Limi.<BR><BR>Return Snapshot: Bafna Pharma. has the highest 1-year return at 198.53%, while Jenburkt Pharma has the lowest at -4.08%. Kilitch Drugs' 1-year return is 3.44%, which is higher than Jenburkt Pharma but significantly lower than Bafna Pharma. Additionally, Amanta Healthcar and Influx Health have a six-month return of 0.00%.

How big is Kilitch Drugs?

As of 31st August, Kilitch Drugs (India) Ltd has a market capitalization of 591.00 Cr, with net sales of 237.21 Cr and net profit of 30.05 Cr over the latest four quarters.

As of 31st August, <BR><BR>Market Cap: Kilitch Drugs (India) Ltd has a market capitalization of 591.00 Cr and is classified as a Micro Cap.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 237.21 Cr, while the sum of Net Profit for the same period is 30.05 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period is March 2026, with Shareholder's Funds amounting to 279.65 Cr and Total Assets totaling 453.17 Cr.

Should I buy, sell or hold Kilitch Drugs (India) Ltd?

Are Kilitch Drugs (India) Ltd latest results good or bad?

Kilitch Drugs (India) Ltd's latest Q4 FY26 results are strong, with a net profit increase of 227.77% QoQ and revenue growth of 66.51% QoQ, marking the highest revenue in eight quarters. However, investor skepticism persists due to past earnings volatility and the stock's recent underperformance.

Kilitch Drugs (India) Ltd's latest results for Q4 FY26 reflect a strong performance, showcasing significant growth in both revenue and net profit. The company reported a net profit of ₹14.52 crores, marking a remarkable increase of 227.77% quarter-on-quarter (QoQ) and 39.62% year-on-year (YoY). Revenue for the quarter reached ₹89.60 crores, which is a 66.51% increase QoQ and a 46.33% increase YoY. This revenue figure is the highest the company has achieved in at least eight quarters.<BR><BR>Additionally, the operating margin improved to 24.71%, the highest in two years, indicating enhanced operational efficiency. However, despite these impressive quarterly results, the stock has seen a decline of 1.61% following the announcement, which suggests some investor skepticism regarding the sustainability of this performance.<BR><BR>While the quarterly results are strong, the company has experienced considerable volatility in its earnings over the past few quarters, raising concerns about the consistency of its financial performance. Furthermore, the stock has underperformed compared to its peers and the broader market over the past year, which might contribute to the cautious sentiment among investors.<BR><BR>In summary, Kilitch Drugs' latest results are good in terms of growth metrics, but the overall outlook is tempered by concerns over volatility and past performance.

What is the bonus history of Kilitch Drugs?

Kilitch Drugs has announced a 1:1 bonus issue effective March 24, 2026, meaning shareholders will receive an additional share for each share held. The record date and ex-date for this bonus are both March 24, 2026.

Kilitch Drugs has a recent bonus history that includes a 1:1 bonus issue, which is set to take effect on March 24, 2026. This means that for every share held, shareholders will receive an additional share. The record date and ex-date for this bonus issue are both the same, March 24, 2026. If you have any further questions about Kilitch Drugs or its financial activities, feel free to ask!

When is the next results date for Kilitch Drugs (India) Ltd?

The next results date for Kilitch Drugs (India) Ltd is 11 February 2026.

The next results date for Kilitch Drugs (India) Ltd is scheduled for 11 February 2026.

Is Kilitch Drugs technically bullish or bearish?

As of December 4, 2025, the technical trend is mildly bearish, indicated by bearish MACD and moving averages, along with mixed signals from Bollinger Bands and Dow Theory, suggesting weak bearish sentiment in the short to medium term.

As of 4 December 2025, the technical trend has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by several key indicators. The MACD is bearish on the weekly chart and mildly bearish on the monthly chart. Bollinger Bands also indicate a mildly bearish trend on both the weekly and monthly time frames. Moving averages are bearish on the daily chart, while the KST shows a mildly bullish stance weekly but is mildly bearish monthly. Dow Theory presents a mixed view with a mildly bearish signal weekly and a mildly bullish signal monthly. Overall, the combination of these indicators suggests a weak bearish sentiment in the short to medium term.

Is Kilitch Drugs overvalued or undervalued?

As of November 25, 2025, Kilitch Drugs is fairly valued with a PE Ratio of 22.32 and strong growth potential, outperforming peers like Sun Pharma and Divi's Lab, while also delivering a 14.87% return compared to the Sensex's 5.59%.

As of 25 November 2025, the valuation grade for Kilitch Drugs has moved from expensive to fair. The company is currently fairly valued based on its financial metrics. Key ratios include a PE Ratio of 22.32, an EV to EBITDA of 19.36, and a PEG Ratio of 0.41, indicating potential for growth relative to its price. <BR><BR>In comparison to its peers, Kilitch Drugs stands out with its fair valuation against Sun Pharma, which is considered expensive with a PE Ratio of 36.81, and Divi's Lab, which is very expensive at a PE Ratio of 68.57. Additionally, while Kilitch has a ROCE of 10.78% and ROE of 10.38%, it has performed well against the Sensex over the past year, returning 14.87% compared to the Sensex's 5.59%.

How has been the historical performance of Kilitch Drugs?

Kilitch Drugs has experienced significant growth in net sales and profitability, with net sales increasing from INR 53.32 crore in March 2020 to INR 198.32 crore in March 2025, and profit after tax rising from INR 0.84 crore to INR 24.94 crore during the same period. The company's earnings per share also surged from INR 0.54 to INR 16.25, reflecting enhanced shareholder value.

Answer:<BR>Kilitch Drugs has shown significant growth in its historical performance, particularly in net sales and profitability over the past several years.<BR><BR>Breakdown:<BR>Kilitch Drugs' net sales have consistently increased from INR 53.32 crore in March 2020 to INR 198.32 crore in March 2025, reflecting a strong upward trend. Total operating income followed a similar trajectory, reaching INR 198.32 crore in March 2025, up from INR 82.49 crore in March 2019. The company's operating profit (PBDIT) also saw substantial growth, rising from INR 4.33 crore in March 2020 to INR 42.63 crore in March 2025, indicating improved operational efficiency. Profit before tax increased from INR 1.61 crore in March 2020 to INR 34.47 crore in March 2025, while profit after tax surged from INR 0.84 crore to INR 24.94 crore in the same period. The earnings per share (EPS) rose significantly from INR 0.54 in March 2020 to INR 16.25 in March 2025, showcasing enhanced shareholder value. On the balance sheet, total assets grew from INR 141.86 crore in March 2020 to INR 309.90 crore in March 2025, with total liabilities also increasing, primarily due to long-term borrowings that began in March 2024. The cash flow from operating activities improved to INR 17 crore in March 2025, compared to a negative cash flow in March 2024, indicating a recovery in operational cash generation. Overall, Kilitch Drugs has demonstrated robust growth in sales, profits, and asset base over the years.

Who are the top shareholders of the Kilitch Drugs?

The top shareholder of Kilitch Drugs is Kilitch Company (Pharma) Limited, holding 41.22%. Other notable shareholders include Dipak Kanayalal Shah with 3.11% and individual investors collectively owning 25.57%.

The top shareholders of Kilitch Drugs are primarily the promoters, with Kilitch Company (Pharma) Limited holding the largest stake at 41.22%. There are no pledged promoter holdings, and mutual funds and foreign institutional investors do not currently hold any shares in the company. Among public shareholders, Dipak Kanayalal Shah is the most significant, holding 3.11%. Additionally, individual investors collectively hold 25.57% of the shares.

Has Kilitch Drugs declared dividend?

Kilitch Drugs has declared a 5% dividend, amounting to 0.5 per share, with an ex-date of September 20, 2019. Despite this, the dividend yield is 0%, as the company has not provided ongoing dividends, though it has shown strong price returns over the years.

Kilitch Drugs has declared a dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 5%<BR>- Amount per share: 0.5<BR>- Ex-date: 20 Sep 19<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was 31.1%, with a dividend return of 0%, resulting in a total return of 31.1%.<BR><BR>For the 1-year period, the price return was 36.77%, with a dividend return of 0%, leading to a total return of 36.77%.<BR><BR>Over the 2-year period, the price return was 110.95%, with a dividend return of 0%, resulting in a total return of 110.95%.<BR><BR>In the 3-year period, the price return was 160.59%, with a dividend return of 0%, leading to a total return of 160.59%.<BR><BR>For the 4-year period, the price return was 171.11%, with a dividend return of 0%, resulting in a total return of 171.11%.<BR><BR>In the last 5 years, the price return was 342.78%, with a dividend return of 0%, leading to a total return of 342.78%.<BR><BR>Overall, Kilitch Drugs has declared a dividend, but the dividend yield remains at 0%. The company has shown substantial price returns over the years, indicating strong performance despite the lack of ongoing dividends.